Shunchang Jiao - Concepedia

Author

Shunchang Jiao

Also Known As

Dilinuer Dilimulati, Jiao S, Jiao, Shunchang, Jinliang Wang, S C Jiao, S Jiao, S. Jiao, S.C. Jiao, SHUN-CHANG JIAO, SHUNCHANG JIAO

218

Publications

Citations

H-Index

Concepts

All Affiliations

Chinese PLA General Hospital Peking University Chinese Academy of Medical Sciences & Peking Union Medical College Chinese People's Liberation Army Peking University Cancer Hospital

About

Shunchang Jiao is an author at Chinese PLA General Hospital specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	33	1.7K
2	Health Sciences	4	4	496
3	Public Health	2	2	45
4	Engineering	1	1	122
5	Natural Sciences	1	1	14

Shunchang Jiao

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng, Gastric Cancer	2014	588
Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer Harold J. Burstein, Yan Sun, Luc Dirix, Journal of Clinical Oncology	2010	523
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Yuankai Shi, Li Zhang, Xiaoqing Liu, The Lancet Oncology Double-blind Phase 3MedicineMetronomic TherapyClinical TrialsIcotinib Versus Gefitinib	2013	420
MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3 Zhongyi Fan, Hanzhi Cui, Xiaojie Xu, Oncotarget OncologyCervical CancerMedicinePathologyStat3 Gene	2015	148
Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications Zhao Wei‐hong, Jiancheng Luo, Shunchang Jiao Scientific Reports EngineeringPathologyComprehensive CharacterizationTumor BiologyTranscriptional Regulation	2014	122
Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study Pengfei Cui, Zhefeng Liu, Guoqiang Wang, Cancer Medicine	2018	112
Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients Liangliang Wu, Deng Zhao-yang, Yaojun Peng, Oncotarget	2017	105
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer Jinwan Wang, Rui‐Hua Xu, Jian Li, Gastric Cancer	2015	103
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis Haiming Yu, Junlan Yang, Shunchang Jiao, Cancer Immunology Immunotherapy Breast OncologyT-regulatory CellImmunologyPathologyHuman Breast Cancer	2015	102
MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression Zhimin Fan, Hao Cui, Hua Yu, Oncogenesis	2016	91

Page 1